Ironwood Investment Management LLC Acquires 172,777 Shares of Quanterix Corporation $QTRX

Ironwood Investment Management LLC increased its holdings in Quanterix Corporation (NASDAQ:QTRX) by 811.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 194,074 shares of the company’s stock after purchasing an additional 172,777 shares during the period. Ironwood Investment Management LLC owned approximately 0.42% of Quanterix worth $1,054,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new stake in Quanterix in the third quarter worth $64,000. HUB Investment Partners LLC purchased a new stake in Quanterix during the second quarter valued at about $81,000. Brevan Howard Capital Management LP bought a new position in shares of Quanterix during the second quarter valued at about $96,000. State of Wyoming increased its holdings in shares of Quanterix by 105.3% in the second quarter. State of Wyoming now owns 14,814 shares of the company’s stock worth $99,000 after buying an additional 7,599 shares during the period. Finally, Intech Investment Management LLC increased its holdings in shares of Quanterix by 13.4% in the third quarter. Intech Investment Management LLC now owns 19,161 shares of the company’s stock worth $104,000 after buying an additional 2,268 shares during the period. Institutional investors own 86.48% of the company’s stock.

Quanterix Trading Down 5.0%

Shares of Quanterix stock opened at $4.76 on Friday. The company’s fifty day simple moving average is $6.31 and its two-hundred day simple moving average is $6.01. The company has a market cap of $223.43 million, a P/E ratio of -1.89 and a beta of 1.05. Quanterix Corporation has a 12-month low of $4.05 and a 12-month high of $8.77.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.11). The company had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $37.95 million. Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%. Analysts predict that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen raised Quanterix from a “sell” rating to a “hold” rating in a research note on Monday, December 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quanterix in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group boosted their price objective on Quanterix from $5.00 to $8.00 and gave the company a “hold” rating in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $11.33.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.